Skip to main content
Premium Trial:

Request an Annual Quote

Premier Biosoft Acquires ProteoIQ Business from NuSep

NEW YORK (GenomeWeb News) – Premier Biosoft said on Monday it has completed the acquisition of NuSep's software business ProteoIQ for an undisclosed amount.

The acquisition launches Palo Alto, Calif.-based Premier into the proteomics market. Premier already operates in the lipidomics, glycomics, and MALDI imaging analysis spaces. In October, it announced an agreement with Agilent Technologies to support the combination of each other's technologies to advance lipidomics research, and in June the company said it had reached a co-marketing and reselling deal with Danaher's AB Sciex for lipidomic research software.

ProteoIQ is software for proteomics analysis that streamlines statistical validation, protein quantification, and comparative proteomics onto one platform, Premier said. The software supports validation of proteins identified by other database search tools such as Mascot, Sequest, or X!Tandem, and can be used for quantitative analysis performed by spectral counting, precursor intensity, iTRACQ, TMT, SILAC, and iCAT workflows.

"For the rapidly growing proteomics market, ProteoIQ is a strategic fit to Premier Biosoft's existing mass spec product offering and helps consolidate our position as a leader for providing informatics tools for mass spectrometry," Premier's CEO Arun Apte said in a statement.

NuSep, a Sydney-based life science firm, announced Premier had made an offer for ProteoIQ earlier this year. It deemed the software business a non-core operation and said that the divestiture would free up the firm to concentrate on its core businesses in the bioseparations market.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.